Summary

Overview
Global Mobile Gamma Cameras Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
A mobile gamma camera system is an imaging technique to generate functional scans of small and large organs including brain, cardiac, neurological, breast, thyroid, pancreas and kidney applications. The mobile gamma camera scans the body by using a procedure that follows injecting a radionucleotide in the body or organ and then recording the resulting radioactivity by image scanning.
The Mobile Gamma Camera is a fully mobile unit. It can be positioned and used at the hospital bed without moving the patient. With an acquisition time of just 2 minutes and a total examination time from the injection of radioisotopes to the final images of just 10 minutes, the 3D Mobile Gamma Camera is a powerful bedside decision-making tool useful even in the emergency room.
Market Dynamics: Drivers and Restraints
Rise in technological advancements
The rise in technological advancements is one of the significant key driver that helps the market to grow during the forecast period. The development of advanced gamma camera systems with improved imaging capabilities is driving the adoption of mobile gamma cameras.
For instance, in June 2023, Serac Imaging launched clinical testing of a portable gamma camera in the US. It is a portable high-resolution hybrid gamma optical camera developed by UK-based company Serac Imaging Systems and is now in clinical testing in the United States. In technology that was originally developed by the University of Leicester for satellites in X-ray astronomy, the device uses radiation to image radioisotopes, which are administered to the patient. This reveals information about the function of the body, for example, if there are blockages.
Some potential applications of the camera include bone, renal and infection imaging, lymphatic imaging, and sentinel lymph node localisation, as well as small organ imaging such as the thyroid.
Hence, the new pharmaceuticals open up new horizons, and we may be able to treat, even cure new diseases. With new cameras and better, quicker detectors, images are sharper, acquisitions are faster, and the radiation burden on patients is reduced. AI may prove to be an important aid to physicians. Furthermore, the global mobile gamma cameras market is also driven by various other factors like, a rise in the prevalence of chronic diseases, increasing adoption of mobile gamma cameras and others will further help the market during the forecast period.
Market Dynamics: Restraint
The introduction of new medical devices like mobile gamma cameras faces regulatory and reimbursement challenges, impacting their adoption and affordability. Also, cost constraints, such as high initial investment and ongoing maintenance, can hamper market accessibility, especially in resource-limited settings, affecting the adoption of these devices.
Segment Analysis
The global mobile gamma cameras market is segmented based on product type, indication, end user and region.
The triple mobile gamma cameras segment from the product type segment accounted for approximately 43.5% of the mobile gamma cameras market share
The triple mobile gamma cameras segment from the product type segment accounted for approximately 43.5% and is expected to be dominated during the forecast period. Among the type segment triple-head mobile gamma cameras are witnessing the fastest growth in the market due to the superior quality of the obtained images, high speed of the resolution of imagining, and cost-effectiveness. These cameras are majorly used for the brain and cardiac SPECT and among healthcare providers and patients the demand for these mobile gamma cameras is high owing to several benefits offered by them.
Also, Triple-head mobile gamma cameras provide higher imaging capabilities by concurrently using three detectors, resulting in improved picture quality, quicker imaging times, and increased patient productivity.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the high prevalence of chronic diseases, such as cancer and heart disease. The demand for diagnostic tools like mobile gamma cameras to detect and monitor these conditions continues to grow, as the population ages. Also, novel product launches, and ongoing advancements in mobile gamma camera technology, including improved image quality and reduced radiation exposure, are driving adoption in the country.
For instance, in May 2020, Digirad stated the launch of updated versions of its Ergo general-purpose nuclear camera and Cardius line of SPECT cameras. The upgraded cameras were developed throughout 2019 and are making their clinical debut this quarter in markets throughout the United States and Canada.
COVID-19 Impact Analysis
The novel coronavirus pandemic has resulted in a significant decline in the treatment of renal diseases worldwide. During the peak of the pandemic, there was a steep reduction in the number of patients with kidney failure accessing treatment such as transplants and dialysis. Such factors may have asserted a negative influence on the steady growth of the mobile gamma cameras industry over the past months.
Market Segmentation
By Product Type
• Triple Mobile Gamma Cameras
• Double Mobile Gamma Cameras
• Single Head Mobile Gamma Cameras
• Hand Held Mobile Gamma Cameras
By Indication
• Cardiac Imaging
• Breast Imaging
• Hepatobiliary Imaging
• GI Imaging
• Renal Imaging
• Brain Imaging
• Others
By End User
• Hospitals
• Ambulatory Surgical Centers
• Cancer Research Institutes
• Specialized Clinics
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Digirad Corporation, DDD-Diagnostic A/S, Spectrum Dynamics Medical, MIE America, LabLogic Systems Ltd, Crystal Photonics, Oncovision Inc, GAEDE Medizinsysteme GmbH, Mediso Ltd, GE Healthcare and among others.
Key Developments
 In May 2022, GE Healthcare announced the launch of its new mobile gamma camera, the Discovery NM/CT 570c. The Discovery NM/CT 570c is a hybrid mobile gamma camera that combines SPECT/CT imaging capabilities in a single device.
Why Purchase the Report?
• To visualize the global mobile gamma cameras market segmentation based on product type, indication, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of mobile gamma cameras market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global mobile gamma cameras market report would provide approximately 77 tables, 79 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Indication
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the technological advancements
4.1.1.2. Rise in the prevalence of chronic diseases
4.1.2. Restraints
4.1.2.1. Stringent regulatory approvals
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Triple Mobile Gamma Cameras*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Double Mobile Gamma Cameras
7.4. Single Head Mobile Gamma Cameras
7.5. Hand-Held Mobile Gamma Cameras
8. By Indication
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Cardiac Imaging*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Breast Imaging
8.4. Hepatobiliary Imaging
8.5. GI Imaging
8.6. Renal Imaging
8.7. Brain Imaging
8.8. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Ambulatory Surgical Centers
9.4. Cancer Research Institutes
9.5. Specialized Clinics
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.5.1. China
10.5.5.2. India
10.5.5.3. Japan
10.5.5.4. Australia
10.5.5.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Digirad Corporation*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. DDD-Diagnostic A/S
12.3. Spectrum Dynamics Medical
12.4. MIE America
12.5. LabLogic Systems Ltd
12.6. Crystal Photonics
12.7. Oncovision Inc
12.8. GAEDE Medizinsysteme GmbH
12.9. Mediso Ltd
12.10. GE Healthcare
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us